Common use of License to Use Improvements Clause in Contracts

License to Use Improvements. Licensee shall own Licensee Improvements, and hereby grants to CSMC the following nonexclusive, royalty-free, fully paid-up rights and licenses to the Licensee Improvements: (a) Except as provided below in this Section 2.5, the right and license to use any tangible or intangible information contained in the Licensee Improvements (so long as CSMC shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for CSMC’s internal teaching and other internal educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and to obtain research funding from Funding Agencies, provided that a copy of any grant application is provided to Licensee, in confidence and for informational purposes only, prior to submission; and (b) Except as provided below in this Section 2.5, the right and license to conduct research using the Licensee Improvements (so long as CSMC shall treat information concerning the License Improvements as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), and to develop, use, make, practice and carry out the Licensee Improvements for CSMC’s internal teaching and internal research and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize any Product. Except as provided in Section 2.3 hereof, CSMC shall not, under any circumstances, grant and/or transfer any rights granted to CSMC under this Section 2.5 to any third party (other than to Licensee or, where required by applicable law, rule, regulation, governmental policy or contract, to any Funding Agency or the United States Government) to commercialize Inventions in the Field of Use resulting directly from the Licensee Improvements as a result of CSMC’s internal research and clinical activities with respect to the Licensee Improvements otherwise permitted by Sections 2.5(a) and (b) above.

License to Use Improvements. Licensee shall own Licensee Improvements, and hereby grants to CSMC the following nonexclusive, royalty-royalty free, fully paid-paid up rights and licenses to the Licensee Improvements: (a) Subject to Licensee’s right to prior review to determine the patentability thereof within thirty (30) days following receipt by Licensee, the right and license to publish the scientific findings from research conducted by or through Licensee or on its behalf by CSMC or the Inventor related to the Licensee Improvements; and provided further that if Licensee determines to file a patent application, Licensee shall have a further thirty (30) day period thereafter to do so and CSMC’s right and license shall be delayed until completion of that period. (b) Except as provided below in this Section 2.52.4, the right and license to use any tangible or intangible information contained in the Licensee Improvements (so long as CSMC shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for CSMC’s internal teaching and other internal educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and to obtain research funding from Funding Agencies, provided that a copy of any governmental and other nonprofit organizations (including grant application is provided to Licensee, in confidence and for informational purposes only, prior to submissionapplications); and (bc) Except as provided below in this Section 2.5, the right 2.4 and license to conduct research using the Licensee Improvements (so long as CSMC shall treat such information concerning the License Improvements as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), the right and license to conduct research using the Licensee Improvements, and to develop, use, make, practice and carry out the Licensee Improvements for CSMC’s internal teaching and internal research and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize any Product. Except as provided in Section Sections 2.3 and 2.6 hereof, CSMC shall not, under any circumstances, grant and/or transfer any rights granted to CSMC under this Section 2.5 2.4 to any third party (other than to Licensee or, where required by applicable law, rule, regulation, governmental policy or contract, to any Funding Agency or the United States Government) to commercialize Inventions in the Field of Use resulting directly from the Licensee Improvements as a result of CSMC’s internal research and clinical activities with respect to the Licensee Improvements otherwise permitted by Sections 2.5(a2.4(b) and (bc) above.

License to Use Improvements. Licensee shall own Licensee Improvements, and Prometheus hereby grants to CSMC and UCLA the following nonexclusive, royalty-free, fully paid-up rights and licenses to the Licensee Prometheus Improvements: (a) Subject to Prometheus' right to prior review to determine the patentability within [***] days following receipt by Prometheus, the right and license to publish the scientific findings from research conducted by or through Prometheus or on its behalf by CSMC, UCLA or their respective investigators, related to the Prometheus Improvements; (b) Except as provided below in this Section 2.52.4 hereof, the right and license to use any tangible or intangible information contained in the Licensee Prometheus Improvements (so long as CSMC and UCLA shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for CSMC’s 's and UCLA's internal teaching and other internal educationally-related and non-commercial (except for charges to its their own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and to obtain research funding from Funding Agencies, provided that a copy of any governmental and other non-profit organizations (including grant application is provided to Licensee, in confidence and for informational purposes only, prior to submissionapplications); and (bc) Except as provided below in this Section 2.52.4 hereof, the right and license to conduct research using the Licensee Improvements (so long as CSMC shall treat information concerning the License Improvements as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof)Prometheus Improvements, and to develop, use, make, practice and carry out the Licensee Prometheus Improvements for CSMC’s 's and UCLA's internal teaching and internal research and non-commercial (except for charges to its their own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize any Product. *** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Except as provided in Section Sections 2.3 and 2.6 hereof, neither CSMC shall notnor UCLA shall, under any circumstances, grant and/or transfer any rights granted to CSMC and UCLA under this Section 2.5 2.4 to any third party (other than to Licensee Prometheus or, where required by applicable law, rule, regulation, governmental policy or contract, to any Funding Agency or the United States Government) to commercialize Inventions in the Field of Use resulting directly from the Licensee Prometheus Improvements as a result of CSMC’s 's and UCLA's internal research and clinical activities with respect to the Licensee Prometheus Improvements otherwise permitted by Sections 2.5(a2.4(b) and (bc) above.

License to Use Improvements. Licensee shall own Licensee Improvements, and Prometheus hereby grants to CSMC and UCLA the following nonexclusive, royalty-free, fully paid-up rights and licenses to the Licensee Prometheus Improvements: (a) Subject to Prometheus' right to prior review to determine the patentability within [***] days following receipt by Prometheus, the right and license to publish the scientific findings from research conducted by or through Prometheus or on its behalf by CSMC, UCLA or their respective investigators, related to the Prometheus Improvements; (b) Except as provided below in this Section 2.52.4 hereof, the right and license to use any tangible or intangible information contained in the Licensee Prometheus Improvements (so long as CSMC and UCLA shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for CSMC’s 's and UCLA's internal teaching and other internal educationally-related and non-commercial (except for charges to its their own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and to obtain research funding from Funding Agencies, provided that a copy of any governmental and other non-profit organizations (including grant application is provided to Licensee, in confidence and for informational purposes only, prior to submissionapplications); and (bc) Except as provided below in this Section 2.52.4 hereof, the right and license to conduct research using the Licensee Improvements (so long as CSMC shall treat information concerning the License Improvements as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof)Prometheus Improvements, and to develop, use, make, practice and carry out the Licensee Prometheus Improvements for CSMC’s 's and UCLA's internal teaching and internal research and non-commercial (except for charges to its their own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize any Product. Except as provided in Section Sections 2.3 and 2.6 hereof, neither CSMC shall notnor UCLA shall, under any circumstances, grant and/or transfer any rights granted to CSMC and UCLA under this Section 2.5 2.4 to any third party (other than to Licensee Prometheus or, where required by applicable law, rule, regulation, governmental policy or contract, to any Funding Agency or the United States Government) to commercialize Inventions in the Field of Use resulting directly from the Licensee Prometheus Improvements as a result of CSMC’s 's and UCLA's internal research and clinical activities with respect to the Licensee Prometheus Improvements otherwise permitted by Sections 2.5(a2.4(b) and (bc) above.

License to Use Improvements. Licensee shall own Licensee Improvements, and hereby grants to CSMC the following license rights to the Licensee Improvements, which rights shall be nonexclusive, royalty-free, fully paid-up rights and licenses subject to the Licensee Improvementsfollowing conditions: (aA) Subject to Licensee's right to prior review to determine the patentability thereof within forty-five (45) days following receipt by Licensee, the right and license to publish the scientific findings from research conducted for Licensee by CSMC with respect to particular and identified Licensee Improvements; (B) Except as provided below in this Section 2.52.4, the right and license to use any tangible or intangible information contained in the Licensee Improvements (so long as CSMC shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for CSMC’s 's internal teaching and other internal educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize or develop such informationinformation and, and with Licensee's prior written consent (not to be unreasonably withheld, delayed or conditioned), to obtain research funding from Funding Agencies, provided that a copy of any governmental and other nonprofit organizations (including grant application is provided to Licensee, in confidence and for informational purposes only, prior to submissionapplications); and (bC) Except as provided below in this Section 2.52.4, the right and license to conduct research using the Licensee Improvements (so long as CSMC shall treat information concerning the License Improvements as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof)Improvements, and to develop, use, make, practice and carry out the Licensee Improvements for CSMC’s 's internal teaching and internal research and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize or develop any Product. Except as provided in Section 2.3 hereof, CSMC shall not, under any circumstances, grant and/or transfer any rights (i) granted to CSMC under this Section 2.5 2.4 to any third party (other than to Licensee or, where required by applicable law, rule, regulation, governmental policy or contract, to any Funding Agency or the United States Government) or (ii) to commercialize or develop Inventions in the Field of Use resulting directly from the Licensee Improvements as a result of CSMC’s 's internal research and clinical activities with respect to the Licensee Improvements otherwise permitted by Sections 2.5(a2.4(b) and (bc) above.